Although no changes in KATII activity were observed in the CIS group, CIS administration significantly increased brain KYNA levels compared to control (124.3 ± 18.3 vs. 52.4 ± 4.5 fmoles/mg protein, respectively) (see Figure 4B). The gene discussed is AADAT; the disease is in situ carcinoma.